Urinary tract infection in infants caused by extended-spectrum beta-lactamase-producing Escherichia coli: comparison between urban and rural hospitals
Community-acquired urinary tract infection (UTI) caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli is an emerging problem. Compared with urban infants, rural infants may encounter different distributions of community-acquired resistant strains and various barriers to efficient management.
A retrospective survey and comparison was conducted for infants with UTI caused by ESBL-producing E. coli admitted to an urban hospital (n = 111) and a rural hospital (n = 48) in southern Taiwan from 2009 to 2012.
Compared with 2009 and 2010, the total number of cases at both hospitals significantly increased in 2011 and 2012 (p < 0.001). Compared with the rural patients, the urban patients were significantly younger, and they had fewer days of fever before and after admission, fewer presentations of poor activity and poor appetite, and a lower serum creatinine level. Most of the patients had no prior history of illness, and we could not identify any significant different risk factors for acquiring ESBL-producing E. coli, such as past antimicrobial use, hospitalization, UTI, and underlying renal diseases, between the urban and rural populations.
The increase in community-acquired UTI in infants caused by ESBL-producing E. coli was similar between the urban and rural populations. Our preliminary data suggest that the rural–urban disparities were probably related to easy access to health care by the urban population. ESBL complicates disease management, and the increase in the prevalence of ESBL producers is a major health concern and requires further healthy carrier and environmental surveillance.
KeywordsAntimicrobial resistance Epidemiology Rural health Health disparity Child
This study was supported by a grant (VGHKS104-082) from Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Compliance with ethical standards
This study was approved by the Institutional Review Board (VGHKS13-CT1-01) of both hospitals.
Conflict of interest
The authors have no conflicts of interest to disclose
- 1.Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana S, Vila J, Garau J (2006) Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 57:780–783Google Scholar
- 2.Ena J, Arjona F, Martinez-Peinado C, Lopez-Perezagua Mdel M, Amador C (2006) Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 68:1169–1174Google Scholar
- 4.Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG (2009) Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 53:2733–2739Google Scholar
- 7.Vu H, Nikaido H (1985) Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams. Antimicrob Agents Chemother 27:393–398Google Scholar
- 8.Cheng MF, Chen WL, Hung WY, Huang IF, Chiou YH, Chen YS, Lee SS, Hung CH, Wang JL (2015) Emergence of extended spectrum-beta-lactamase-producing Escherichia coli O25b-ST131: a major community-acquired uropathogen in infants. Pediatr Infect Dis J 34:469–475Google Scholar
- 9.Chung HC, Lai CH, Lin JN, Huang CK, Liang SH, Chen WF, Shih YC, Lin HH, Wang JL (2012) Bacteremia caused by extended-spectrum-beta-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 56:618–622Google Scholar
- 10.Clinical Laboratory Standards Institute (2009) Performance standards for antimicrobial susceptibility testing. 19th Informational supplement M100-S19. Clinical Laboratory Standards Institute, WayneGoogle Scholar
- 21.Arpin C, Dubois V, Coulange L, Andre C, Fischer I, Noury P, Grobost F, Brochet JP, Jullin J, Dutilh B, Larribet G, Lagrange I, Quentin C (2003) Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 47:3506–3514CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, Perez-Cano R, Pascual A (2004) Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42:1089–1094Google Scholar
- 25.Rogers BA, Sidjabat HE, Paterson DL (2011) Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66:1–14Google Scholar
- 26.Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R (2004) Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 42:4769–4775CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Blanc V, Leflon-Guibout V, Blanco J, Haenni M, Madec JY, Rafignon G, Bruno P, Mora A, Lopez C, Dahbi G, Dunais B, Anastay M, Branger C, Moreau R, Pradier C, Nicolas-Chanoine MH (2014) Prevalence of day-care centre children (France) with faecal CTX-M-producing Escherichia coli comprising O25b:H4 and O16:H5 ST131 strains. J Antimicrob Chemother 69:1231–1237Google Scholar
- 29.Guimaraes B, Barreto A, Radhouani H, Figueiredo N, Gaspar E, Rodrigues J, Torres C, Igrejas G, Poeta P (2009) Genetic detection of extended-spectrum beta-lactamase-containing Escherichia coli isolates and vancomycin-resistant enterococci in fecal samples of healthy children. Microb Drug Resist 15:211–216CrossRefPubMedGoogle Scholar
- 31.Al-Mayahie SM (2013) Phenotypic and genotypic comparison of ESBL production by vaginal Escherichia coli isolates from pregnant and non-pregnant women. Ann Clin Microbiol Antimicrob 12:7Google Scholar
- 32.Decre D, Gachot B, Lucet JC, Arlet G, Bergogne-Berezin E, Regnier B (1998) Clinical and bacteriologic epidemiology of extended-spectrum beta-lactamase-producing strains of Klebsiella pneumoniae in a medical intensive care unit. Clin Infect Dis 27:834–844Google Scholar
- 33.Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palzkill T, Arvin AM (1992) Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 36:1991–1996CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Clinical Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing. 21th Informational supplement M100-S21. Clinical Laboratory Standards Institute, WayneGoogle Scholar